Rosetta Genomics Aims to Launch Blood-Based miRNA Colon Cancer Test in 2010

According to recently released data, the test, dubbed miRscreen Colon, can use two miRNAs to identify the disease with 91 percent sensitivity and 72 percent specificity.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.